Polymorphic Form Characterization for Pharmaceutical Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The pharmaceutical industry faces challenges in maintaining consistent polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, which affects the reliability of formulations and stability, leading to variations in dosage forms and potential toxicological effects due to impurities.
Innovation Solution
A novel crystalline form of the compound, characterized by specific powder X-ray diffraction patterns and solid-state NMR spectra, is developed to ensure consistent physical properties and stability, including improved solubility and dissolution rates, and methods for preparing these forms are outlined to achieve high purity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple polymorphic forms of the compound are used, then manufacturing flexibility is improved, but formulation reliability and stability deteriorate due to variations in physical properties
Solution Approach 1:
The patent identifies and characterizes multiple polymorphic forms (Forms I, II, III, IV, V, VI, VII) of Compound 1 with distinct crystal structures and physical properties. Each form has specific X-ray diffraction patterns, melting points, and solubility characteristics. By establishing clear parameter definitions for each polymorph, the patent enables selective use of appropriate forms for different manufacturing needs while maintaining formulation reliability through consistent characterization.
Solution Approach 2:
The patent segments the compound into distinct polymorphic forms, each with unique identifying characteristics. Forms I through VII are differentiated by their crystal packing arrangements, X-ray diffraction patterns, and physical properties. This segmentation allows manufacturers to select specific forms based on desired properties while ensuring consistent quality control through form-specific characterization parameters.
2Productivity
If polymorphic forms with different crystal structures are used, then solubility and dissolution rates can be optimized, but manufacturing consistency deteriorates due to variations in physical properties
Solution Approach 1:
The patent systematically varies crystal structure parameters across different polymorphic forms to optimize dissolution rates. Forms with different packing densities and lattice energies exhibit distinct solubility and dissolution characteristics. By defining specific X-ray diffraction patterns and physical property ranges for each form, the patent enables selection of optimal forms for rapid dissolution while maintaining manufacturing consistency through rigorous form identification and quality control.
3Productivity
If impurities are present in polymorphic forms, then manufacturing yield is improved, but toxicological safety deteriorates
Solution Approach 1:
The patent replaces reliance on mechanical purification methods with a systematic approach based on polymorph-specific characterization and identification. By using X-ray diffraction patterns, melting point ranges, and solubility profiles as identification criteria, the patent enables detection and control of impurities that may accompany different polymorphic forms, ensuring toxicological safety while maintaining manufacturing yield.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel crystalline form enhances the stability, bioavailability, and manufacturability of the compound, reducing impurities and improving handling and processing, leading to more effective pharmaceutical formulations for treating abnormal cell growth, such as cancer.
Implementation Method 1
crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2θ) of 5.1 ± 0.1
Implementation Method 2
powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 7.9 ± 0.1, 10.7 ± 0.1, and 18.2 ± 0.1
Implementation Method 3
solid state NMR 13
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to crystalline polymorphic and amorphous form of 6- [2- (methylcarbamoyl) phenyl sulfanyl] -3-E- [2- (pyridin-2- yl) ethenyl] indazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.